Pharmaceuticals, Biotechnology and Life Sciences
STA Pharmaceutical, a WuXi AppTec subsidiary has signed a supply agreement with the oncology-focused biopharmaceutical company, Tesaro, for certain starting and intermediate materials for Zejula (Niraparib).
The U.S. Food and Drug Administration has approved Tesaro’s Zejula (niraparib) for the maintenance treatment (intended to delay cancer growth) of adult patients with recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer, whose tumors have completely or partially shrunk (complete or partial response, respectively) in response to platinum-based chemotherapy.